CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement. CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, reported its unaudited financial results for ...

CSPC has good financial health. As of 2021, it has almost no debt and over CNY 9 billion of cash on balance sheet, as well as consistently positive operating cash flow, so it is well-positioned to ...

AstraZeneca (AZN) on Friday announced a strategic research collaboration with China-based CSPC Pharmaceuticals Group to advance the development of oral drug candidates with the potential to treat ...

CSPC Pharmaceutical will release earnings for Q4 on March 22. Analysts predict CSPC Pharmaceutical will report earnings per share of CNY 0.081.

July 30 (Reuters) - U.S. drugmaker Madrigal Pharmaceuticals (MDGL.O) has struck a licensing deal with CSPC Pharmaceutical Group (1093.HK) that could be worth more than $2 billion for the Chinese ...

CSPC Pharma gets an upfront fee of up to $150 million, development payments of up to $135 million and further fees of up to $1.55 billion if it hits sales milestones, as well as royalties.

CSPC Pharmaceutical Group Limited (CSPCY) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings.

Overview: CSPC Innovation Pharmaceutical Co., Ltd. focuses on the research, development, production, and sales of biopharmaceuticals, APIs, and functional foods both in China and internationally ...

CSPC Pharmaceutical Group Limited has announced the on-market purchase of 7 million shares, accounting for approximately 0.059% of the total shares issued, at an average price of HK$6.929 per share.

February 24, 20203:46 PM UTCUpdated ago Feb 24 (Reuters) - CSPC Pharmaceutical Group Ltd: * FY NET PROFIT ATTRIBUTABLE FOR CSPC INNOVATION PHARMACEUTICAL 272.7 MILLION RMB VERSUS 223.8 MILLION RMB ...

A recent pullback in the shares of Hong Kong listed CSPC Pharmaceutical (1093.HK) could be a good buying opportunity, according to Jefferies. The broker believes the weakness in the drug maker's ...